174 related articles for article (PubMed ID: 34692501)
1. Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer.
Meng X; Ahmed M; Courtney KD; Arafat W; Ibrahim I; Margulis V; Nichols C; Bagrodia A
Front Oncol; 2021; 11():724682. PubMed ID: 34692501
[TBL] [Abstract][Full Text] [Related]
2. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
Gizzi M; Oberic L; Massard C; Poterie A; Le Teuff G; Loriot Y; Albiges L; Baciarello G; Michels J; Bossi A; Blanchard P; Escudier B; Fizazi K
Eur J Cancer; 2016 Dec; 69():151-157. PubMed ID: 27821318
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy.
Shields LBE; Daniels MW; Mar N; Rezazadeh Kalebasty A
World J Clin Oncol; 2021 Mar; 12(3):183-194. PubMed ID: 33767973
[TBL] [Abstract][Full Text] [Related]
4. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area.
Piketty AC; Fléchon A; Laplanche A; Nouyrigat E; Droz JP; Théodore C; Fizazi K
Br J Cancer; 2005 Oct; 93(8):909-14. PubMed ID: 16205699
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin prophylaxis is not associated with decreased incidence of venous thromboembolism in testicular germ cell tumor patients receiving chemotherapy.
Hapakova N; Chovanec M; Rejlekova K; Kalavska K; Obertova J; Palacka P; De Angelis V; Sycova-Mila Z; Mardiak J; Mego M
Neoplasma; 2022 Mar; 69(2):456-463. PubMed ID: 35068164
[TBL] [Abstract][Full Text] [Related]
6. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.
Moore RA; Adel N; Riedel E; Bhutani M; Feldman DR; Tabbara NE; Soff G; Parameswaran R; Hassoun H
J Clin Oncol; 2011 Sep; 29(25):3466-73. PubMed ID: 21810688
[TBL] [Abstract][Full Text] [Related]
7. High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy.
Solari L; Krönig M; Ihorst G; Drognitz K; Heinz J; Jilg CA; Schultze-Seemann W; Engelhardt M; Waller CF
Urol Int; 2016; 96(4):399-405. PubMed ID: 27074038
[TBL] [Abstract][Full Text] [Related]
8. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy.
Srikanthan A; Tran B; Beausoleil M; Jewett MA; Hamilton RJ; Sturgeon JF; O'Malley M; Anson-Cartwright L; Chung PW; Warde PR; Winquist E; Moore MJ; Amir E; Bedard PL
J Clin Oncol; 2015 Feb; 33(6):582-7. PubMed ID: 25605848
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
10. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy.
Honecker F; Koychev D; Luhmann AD; Langer F; Dieckmann KP; Bokemeyer C; Oechsle K
Onkologie; 2013; 36(11):663-8. PubMed ID: 24192771
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.
Lee YG; Lee E; Kim I; Lee KW; Kim TM; Lee SH; Kim DW; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):670-5. PubMed ID: 25672586
[TBL] [Abstract][Full Text] [Related]
13. Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.
Funt SA; McHugh DJ; Tsai S; Knezevic A; O'Donnell D; Patil S; Silber D; Bromberg M; Carousso M; Reuter VE; Carver BS; Sheinfeld J; Motzer RJ; Bajorin DF; Bosl GJ; Feldman DR
Oncologist; 2021 Jun; 26(6):483-491. PubMed ID: 33586274
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of thromboembolic events in patients with nephrotic syndrome.
Pincus KJ; Hynicka LM
Ann Pharmacother; 2013 May; 47(5):725-34. PubMed ID: 23613095
[TBL] [Abstract][Full Text] [Related]
15. Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Verhage RJ; van der Horst S; van der Sluis PC; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2012 Feb; 19(2):684-92. PubMed ID: 21837523
[TBL] [Abstract][Full Text] [Related]
16. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Fehr M; Hawle H; Hayoz S; Thuss-Patience P; Schacher S; Riera Knorrenschild J; Dürr D; Knoefel WT; Rumpold H; Bitzer M; Zweifel M; Samaras P; Mey U; Küng M; Winterhalder R; Eisterer W; Hess V; Gérard MA; Templeton A; Stahl M; Ruhstaller T; ; ; ;
BMC Cancer; 2020 Feb; 20(1):166. PubMed ID: 32111181
[TBL] [Abstract][Full Text] [Related]
17. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.
Zareba P; Patterson L; Pandya R; Margel D; Hotte SJ; Mukherjee SD; Elavathil L; Daya D; Shayegan B; Pinthus JH
Urol Oncol; 2014 Oct; 32(7):975-80. PubMed ID: 25027682
[TBL] [Abstract][Full Text] [Related]
18. Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up.
de Luca I; Sorino M; De Luca L; Colonna P; Del Salvatore B; Corlianò L
Int J Cardiol; 2005 Jul; 102(3):447-54. PubMed ID: 16004890
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies.
Patti G; Pecen L; Manu MC; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; Caterina R
Int J Cardiol; 2020 Nov; 318():67-73. PubMed ID: 32574823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
